CNV
6
1
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Evaluation of Retinal Structure With High Resolution Optical Coherence Tomography (OCT)
Reinterpretation of CNV With Unknown Significance: a 5-year Retrospective Analysis
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration